Insider Selling: Oscar Health (NYSE:OSCR) Director Sells $806,000.00 in Stock

Key Points

• Oscar Health director Vanessa Ames Wittman sold 25,000 shares for approximately $806,000 at an average price of $32.24 under a pre-arranged Rule 10b5-1 plan, reducing her ownership by 18.23%.
• Oscar Health shares recently traded at $30.65, with the stock near its 12-month high of $34.48 and up significantly from its 12-month low of $10.69.
• The company reported strong quarterly results, including $1.10 in EPS versus $0.40 expected and 70.4% year-over-year revenue growth, while analysts maintained a consensus “Hold” rating with a $33.90 price target.

Oscar Health, Inc. (NYSE:OSCR - Get Free Report) Director Vanessa Ames Wittman sold 25,000 shares of the firm's stock in a transaction on Friday, September 18th. The stock was sold at an average price of $32.24, for a total value of $806,000.00. Following the completion of the transaction, the director owned 112,121 shares in the company, valued at approximately $3,614,781.04. This trade represents a 18.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oscar Health Stock Performance

Shares of NYSE:OSCR traded down $0.64 during trading on Tuesday, hitting $30.65. The company's stock had a trading volume of 8,238,111 shares, compared to its average volume of 7,024,898. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.09 and a quick ratio of 1.09. Oscar Health, Inc. has a 12 month low of $10.69 and a 12 month high of $34.48. The firm has a market cap of $9.46 billion, a price-to-earnings ratio of 21.89, a P/E/G ratio of 0.37 and a beta of 2.37. The company has a 50-day moving average of $30.75 and a 200-day moving average of $24.22.

Oscar Health (NYSE:OSCR - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.70. The firm had revenue of $4.88 billion during the quarter, compared to the consensus estimate of $4.73 billion. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The company's revenue for the quarter was up 70.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.89) EPS. On average, sell-side analysts expect that Oscar Health, Inc. will post 1.74 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. CoreCap Advisors LLC increased its holdings in Oscar Health by 526.3% in the 2nd quarter. CoreCap Advisors LLC now owns 1,190 shares of the company's stock worth $34,000 after buying an additional 1,000 shares during the period. GAMMA Investing LLC boosted its stake in shares of Oscar Health by 32.9% in the second quarter. GAMMA Investing LLC now owns 1,441 shares of the company's stock worth $41,000 after buying an additional 357 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Oscar Health in the first quarter valued at approximately $49,000. FNY Investment Advisers LLC purchased a new position in shares of Oscar Health during the 2nd quarter valued at approximately $57,000. Finally, Allworth Financial LP grew its position in Oscar Health by 124.9% during the second quarter. Allworth Financial LP now owns 2,031 shares of the company's stock valued at $58,000 after buying an additional 1,128 shares during the period. 75.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Zacks Research upgraded Oscar Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, July 6th. UBS Group raised their price objective on Oscar Health from $20.00 to $26.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. Bank of America lifted their price target on shares of Oscar Health from $28.00 to $30.00 and gave the stock an "underperform" rating in a research note on Thursday, September 17th. Robert W. Baird increased their target price on Oscar Health from $27.00 to $33.00 and gave the stock a "neutral" rating in a research note on Thursday, September 17th. Finally, Stephens reiterated an "equal weight" rating and issued a $34.00 target price on shares of Oscar Health in a report on Thursday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Oscar Health currently has an average rating of "Hold" and a consensus price target of $33.90.

About Oscar Health

Oscar Health, Inc is a technology-focused health insurance company that offers health plans and related services to individuals, families and small businesses in the United States. The company's primary business is providing Individual and Family plans through the Affordable Care Act marketplaces, along with health insurance options for small-group employers in select markets.

Oscar combines insurance coverage with digital tools designed to help members manage their care. Its offerings include online and mobile enrollment, virtual care, provider search and navigation services, claims and benefits information, and access to care teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.